NEW YORK, Jan. 9, 2012 /PRNewswire/ -- MolecularHealth, a clinico-molecular informatics company, today announced the commercialization and planned roll-out of two next generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices for patients.
"With the cost of producing genomic information falling drastically and clinical data becoming increasingly accessible, today's remaining challenge resides in the analysis and interpretation of this information," said Friedrich von Bohlen, Ph.D., MolecularHealth's chief executive officer. "MolecularHealth has developed and is commercializing solutions that translate clinical and molecular data into actionable information, delivering precision medicine – safe and efficacious treatment decisions."
The company announced the planned commercial launch of two product lines in drug safety and molecularly-guided treatment decision support. Molecular Analysis of Side Effects (MASE) combines adverse event information with clinico-molecular knowledge about drug activity within a patient.
The company's molecularly-guided treatment decision support solutions, which will initially be available for use in oncology, integrate molecular data – including whole genome sequences – with clinical information about a patient, translating these data into evidence-based treatment strategies for marketed and clinical stage therapies.
"When we founded SAP forty years ago, we believed that organizing previously disaggregate data and systems could make for more efficient, effective enterprise resource planning," said Dietmar Hopp, co-founder and former Chairman and CEO of SAP and, through dievini Hopp BioTech, the sole investor in MolecularHealth. "Today, I see a similar opportunity in the healthcare sector, and MolecularHealth is paving the way through the integration of clinical and molecular information."
The company also announced the initiation of its U.S. commercial operations in New York under the leadership of Jeffrey D. Marrazzo, former executive with Generation Health, a genetic benefit management company.
"In the next five years, most cancer patients will have molecular and genomic profiles of their tumors," said Mr. Marrazzo. "MolecularHealth's mature technology platform and clinical and research relationships, including with the M.D. Anderson Cancer Center, will enable us to help physicians and other stakeholders translate this information into the language of the user."
In the coming months, the company will make a series of announcements critical to the advancement of precision medicine.
About MolecularHealthMolecularHealth is on the forefront of precision medicine, applying a pioneering approach called clinico-molecular informatics to patient treatment. The company's knowledge-driven solutions translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer and more effective drug choices. For patients at risk of a serious adverse drug event, or for those awaiting their next course of cancer treatment, precision matters. MolecularHealth's offerings range from a next generation drug safety assessment tool that analyzes the molecular basis of adverse events to the first oncology decision support solution that transforms whole genome sequencing data into evidence-based treatment strategies.
The company maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York and is backed by the co-founder, former chairman and chief executive officer of SAP, Dietmar Hopp. MolecularHealth has successfully built upon its heritage as one of the leading software analysis providers for the Human Genome Project. In 2008, MolecularHealth entered into a ten-year strategic affiliation agreement with The University of Texas M.D. Anderson Cancer Center to pursue joint research projects in the area of molecular medicine for the discovery, validation and/or development of biomarkers, drug targets, combinatorial treatments, alternative medical uses, adverse drug reactions or modes of action of drugs and other compositions. The company is led by a team of seasoned entrepreneurs, scientists and technologists, including founding members of Generation Health, LION Bioscience, Model N Life Sciences and Xapien. Media Contacts
Corporate ContactTony Russo, Ph.D.
Eric M. StoneMatt Middleman, M.D.
Vice President, Sales and MarketingRusso Partners
T: (713) 834-9990T: 212-845-4251
Copyright©2010 PR Newswire.
All rights reserved